ALK and non-small cell lung carcinoma: We tested several c-MET inhibitors, including Crizotinib (Xalkori), an FDA-approved compound (Rodig and Shapiro, 2010), for late-stage non-small-cell lung cancers that express the abnormal anaplastic lymphoma kinase.